Exscientia looks inward

After spending six years building its artificial intelligence drug discovery platform and working with pharma partners, Exscientia Ltd. aims to use the bulk of the $26 million raised in a series B round to build its own internal therapeutics pipeline.

CEO Andrew Hopkins said that because the biotech’s AI-driven Centaur Chemist drug discovery platform can generate new candidates more quickly and cheaply than conventional small molecule methods, the goal is to produce a portfolio of molecules within a given disease area with the same time and expenditure typically needed for a single candidate...